Trial Information

Summary: RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Novartis Oncology is conducting this clinical research study is to determine if an investigational drug is safe and effective in people who have advanced pancreatic neuroendocrine tumors. This cancer is also known as islet cell carcinoma. The purpose of this clinical research study is to learn if the investigational drug can shrink or slow the growth of the tumors. In order to determine the safety and effectiveness of the investigational drug, the study doctor will monitor the physical state and well being of participants, evaluate changes in the size of their tumors, and perform laboratory tests. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will be asked to take 2 tablets (5 mg each) orally, once a day for a set number of days
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 22, 2008 at 2:59:51 PM